2016
Vaccination strategies against respiratory syncytial virus
Yamin D, Jones FK, DeVincenzo JP, Gertler S, Kobiler O, Townsend JP, Galvani AP. Vaccination strategies against respiratory syncytial virus. Proceedings Of The National Academy Of Sciences Of The United States Of America 2016, 113: 13239-13244. PMID: 27799521, PMCID: PMC5135296, DOI: 10.1073/pnas.1522597113.Peer-Reviewed Original ResearchConceptsRespiratory syncytial virusSyncytial virusVaccination strategiesAge-specific vaccination strategiesRSV vaccine candidatesSubstantial indirect protectionInfectious viral loadOngoing clinical trialsWeekly incidence ratesTargeting of childrenDifferent age groupsInfected childrenRSV vaccinationVaccination uptakeInfant hospitalizationViral loadVaccine mechanismVaccination programClinical trialsIncidence rateCommon causeRSV incidenceVaccine candidatesAge groupsRSV symptomsCost-Effectiveness of Pertussis Vaccination During Pregnancy in the United States
Atkins KE, Fitzpatrick MC, Galvani AP, Townsend JP. Cost-Effectiveness of Pertussis Vaccination During Pregnancy in the United States. American Journal Of Epidemiology 2016, 183: 1159-1170. PMID: 27188951, PMCID: PMC4908210, DOI: 10.1093/aje/kwv347.Peer-Reviewed Original ResearchConceptsMaternal vaccinationAdult vaccinationWorld Health Organization criteriaPrimary vaccination seriesVaccination of mothersRecent epidemiologic evidenceAge-stratified transmission modelMaternal antibody transferPertussis vaccinationPostpartum vaccinationVaccination seriesAntibody transferEpidemiologic evidenceOrganization criteriaPertussis incidenceDisease burdenCurrent recommendationsSevere casesVaccinationInfantsPregnancyDirect protectionUS mothersMothersPertussisCost-effectiveness of next-generation vaccines: The case of pertussis
Fitzpatrick MC, Wenzel NS, Scarpino SV, Althouse BM, Atkins KE, Galvani AP, Townsend JP. Cost-effectiveness of next-generation vaccines: The case of pertussis. Vaccine 2016, 34: 3405-3411. PMID: 27087151, DOI: 10.1016/j.vaccine.2016.04.010.Peer-Reviewed Original ResearchConceptsNext-generation vaccinesDuration of protectionAdult boostersChildhood seriesAge-structured transmission modelVaccination coverage ratesCases of pertussisPublic health challengePerfect efficacyPertussis vaccinationPertussis vaccinePertussis incidenceCurrent vaccinesNew vaccinesPotential vaccinesGreater efficacyVaccineVaccine improvementHealth challengesAverage durationHealth benefitsEfficacyDoseShort durationPertussis
2015
Optimizing age of cytomegalovirus screening and vaccination to avert congenital disease in the US
Alfaro-Murillo JA, Townsend JP, Galvani AP. Optimizing age of cytomegalovirus screening and vaccination to avert congenital disease in the US. Vaccine 2015, 34: 225-229. PMID: 26631416, DOI: 10.1016/j.vaccine.2015.11.039.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overChildChild, PreschoolCytomegalovirus InfectionsCytomegalovirus VaccinesDisease Transmission, InfectiousFemaleHumansImmunization ScheduleInfantInfant, NewbornInfectious Disease Transmission, VerticalMaleMass ScreeningMiddle AgedUnited StatesYoung AdultConceptsVaccine waningVaccine efficacyOptimal ageCMV vaccine candidatesLongitudinal clinical evaluationChild-bearing yearsYears of ageTransmission dynamicsCMV prevalenceCMV vaccinationCytomegalovirus ScreeningSeronegative femalesCongenital infectionCytomegalovirus infectionVaccine protectionSuch vaccinationClinical evaluationClinical trialsHearing lossVaccine candidatesVaccinationDemographic dataCongenital diseaseCognitive deficitsIndirect protection